To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

NCT06470633 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HR+/HER2- Breast Cancer

Interventions

DRUG: Adebrelimab
PROCEDURE: High Intensity Focused Ultrasoun（HIFU）
DRUG: Cyclophosphamide
DRUG: Epirubicin
DRUG: Docetaxel

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]